Tamarack Advisers’s NovoCure NVCR Stock Holding History

Tamarack Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-150,000	Closed	-$9.64M	–	34
2019 Q2	$9.64M	Buy	+150,000	New	+$7.6M	2.93%	14
2019 Q1	–	Sell	-670,000	Closed	-$22.4M	–	24
2018 Q4	$22.4M	Buy	670,000 +35,000	+6%	+$1.28M	9.15%	4
2018 Q3	$33.4M	Sell	635,000 -465,000	-42%	-$18.5M	9.54%	2
2018 Q2	$34.4M	Sell	1,100,000 -15,000	-1%	-$417K	11.53%	1
2018 Q1	$24.3M	Buy	1,115,000 +60,000	+6%	+$1.29M	11.56%	1
2017 Q4	$21.3M	Buy	1,055,000 +311,446	+42%	+$6M	11.63%	1
2017 Q3	$14.8M	Sell	743,554 -161,446	-18%	-$3.17M	9.04%	2
2017 Q2	$15.7M	Sell	905,000 -85,750	-9%	-$1.11M	9.14%	2
2017 Q1	$8.03M	Buy	990,750 +165,750	+20%	+$1.2M	5.01%	7
2016 Q4	$6.48M	Buy	825,000 +50,000	+6%	+$402K	4.58%	12
2016 Q3	$6.56M	Buy	+775,000	New	+$7.07M	2.06%	17

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tamarack Advisers's NVCR Position: Q3 2019 in Review

Tamarack Advisers sold out of NovoCure (NVCR) in Q3 2019, closing a stake of 150,000 shares — an estimated $9.64M sold.

Tamarack Advisers first reported a position in NVCR in Q3 2016 and held it in 11 quarters. The position peaked at $34.4M in Q2 2018. 240 funds tracked by Wall St. Rank hold NVCR as of Q3 2019.

Tamarack Advisers reported no remaining NovoCure position as of Q3 2019 after selling out during the quarter.
Tamarack Advisers sold 150,000 NovoCure shares in Q3 2019, an estimated $9.64M.
Tamarack Advisers first reported a position in NovoCure in Q3 2016 and held it in 11 quarters.
Tamarack Advisers's NovoCure position peaked at $34.4M in Q2 2018.
240 funds tracked by Wall St. Rank held NovoCure as of Q3 2019.

Based on Tamarack Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.